DOI: 10.25881/20728255_2021_16_3_73


Tyurin V.P., Pronin A.G.

Pirogov National Medical and Surgical Center, Moscow


Diagnosis and choice of treatment options for pulmonary embolism (PE) is one of the most important problems of modern medicine. The introduction of CT- angiography into practice has significantly improved the diagnosis of this disease. The creation of a stratification of the risk of early death and the optimization of anticoagulant therapy set a new vector in approaches to the treatment of PE. This article analyzes the current literature data and the results of our own observations in the treatment of pulmonary embolism.

Keywords: pulmonary embolism, risk of early death, thrombolytic therapy, anticoagulant therapy, chronic thromboembolic pulmonary hypertension.


1. Karsanov AM, Kul’chiev AA, Karaev TR, et al. The role of current methods of X-ray diagnosis in case of intraabdominal suppurative complications caused bu colonic diseases. Pirogov Journal of Surgery. 2015; 5: 75-79. (In Russ). doi: 10.17116/hirurgia2015575–79.

2. Kul’chiev AA, Morozov AA, Kul’chieva LM. Visualization diagnostics of pulmonary thromboembolism. Сhief physician of the South of Russia. 2021; 76(1): 9-14 (In Russ).

3. Tseng ZH, Olgin JE, Vittinghoff E, et al. Prospective countywide surveillance and autopsy characterization of sudden cardiac death (POST SCD Study). Circulation. 2018; 137(25): 2689-700. doi: 01l161/circulatiоnaha1l17.033427.

4. Bagrova I.V., Kuharchik G.A., Serebryakova V.I. et al. The modern approaches to diagnostics of pulmonary embolism. Flebologiya. 2012; 4: 35-42 (In Russ).

5. Berns SA, Shmidt EA, Neeshpapa AG, et al. Risk factors associated with the development of death events during the first year of follow-up after pulmonary thromboembolism. Medical Council. 2019; 5: 80-85 (In Russ). doi: 10.21518/2079–701X–2019–5–80–85.

6. Bokeriya LA, Zatevakhin II, Kiriyenko AI, et al. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications (VTE). Flebologiya. 2015; 9(4): 2-52 (In Russ).

7. Bikdeli B, Lobo JL, Jimenez D, et al. Early use of echocardiography in patients with acute pulmonary embolism: Findings from the RIETE registry. J Am Heart Assoc. 2018; 7(17): e009042. doi:10.1161/JAHA.118.009042.

8. Gilyarov MY, Konstantinova EV. How new approaches to the treatment of pulmonary embolism affect the outcome of the disease? Medical Council. 2017; 7: 48-55. (In Russ). doi: 10.21518/2079–701X–2017–7–48–55.

9. Bates SM, Greer IA, Middeldorp S, et al. American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2): 691-736.

10. Belyalov F.I. Clinical guidelines for cardiology. 2017: 288. (In Russ).

11. Konstantinides S.V, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). European Heart Journal. 2020; 41: 543-603. doi: 10.1093/eurheartj/ehz405.

12. Gilyarevskiy SR. The advanced tactics of the management of patients with venous thromboembolism: the role of rivaroxaban at various stages of treatment. Rational Pharmacotherapy in Cardiology. 2016; 12(3): 337-343. (In Russ). doi: 10.20996/1819–6446–2016–12–3–337–343.

13. Margolis JM, Deitelzweig S, Kline J, Tran O, et al. Shorter hospital stays and lower costs for rivaroxaban compared with warfarin for venous thrombosis admissions. Journal of the American Heart Association. 2016; 5: e003788. doi: 10.1161/JAHA.116.003788.

14. Barco S, Lankeit М, Binder Н, Schellong S, еt al. Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial. Thromb Haemost, 2016; 116(1): 191-7. doi: 10.1160/TH16–01–0004.

15. Becattini C, Agnelli G. Acute treatment of venous thromboembolism. Blood. 2020; 135(5): 305-316. doi: 10.1182/blood.2019001881.

16. Otieno R, Okpo E, Forster R. Home treatment versus in patient treatment for deep vein thrombosis. Cochrane Database Syst Rev. 2018; 1: CD003076. doi: 10.1002/14651858.CD003076.pub3.

17. Jiménez D, Bikdeli B, Barrios D, et al. Epidemiology, patterns of care and mortality for patients with hemodynamically unstable acute symptomatic pulmonary embolism. International Journal of Cardiology. 2018; 269: 327-33. doi: 101016/j.ijcard.2018.07.059.

18. Nikulina NN, Terekhovskaya YuV. Epidemiology of pulmonary embolism in today’s context: analysis of incidence, mortality and problems of their study. Russian Journal of Cardiology. 2019; 24(6): 103-108. (In Russ). doi: 10.15829/1560–4071–2019–6–103–108.

19. Kochmareva ЕА , Kokorin VА, Volkova АL, et al. Predictors of short term outcomes in high and moderate risk pulmonary thromboembolism. Russian Journal of Cardiology. 2017; (9): 7-12. (In Russ). doi: 10.15829/1560–4071–2017–9–7–12.

20. Martinez C, Cohen AT, Bamber L, Rietbrock S. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb Haemost. 2014; 112(2): 255-63. doi: 10.1160/TH13–09–0793.

21. Zatevakhin II, Kiriyenko AI, Stoiko YuM, et al. Diagnostics and Treatment of Chronic Venous Disease: Guidelines of Russian Phlebological Association. Flebologiya. 2018; 12(3): 146-240. (In Russ). doi:10.17116/flebo20187031146.

22. Novikova NA, Shilova AS. Prevention of venous thromboembolic complications in primary care. Meditsinskiy sovet. 2017; 7: 43-47. (In Russ). doi: 10.21518/2079–701X–2017–7–43–47.

23. Podlipaeva AA, Mullova IS, Pavlova TV, et al. Novel biological markers for the diagnosis and prediction of mortality risk in patients with pulmonary embolism. Russian Journal of Cardiology. 2020; 25(4S): 4202. (In Russ). doi:10.15829/1560–4071–2020–4202.

24. Bajaj A, Saleeb M, Rathor P, et al. Prognostic value of troponins in acute nonmassive pulmonary embolism: A meta-analysis. Heart&Lung. 2015; 44(4): 327-334. doi:10.1016/j. hrtlng.2015.03.007.

25. Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J. 2017; 49(2): 1601792. doi:101183/13993003.01792–2016.

26. Gall H, Hoeper MM, Richter MJ, et al. An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan. Eur Respir Rev. 2017; 26: 160121. doi:10.1183/16000617.0121–2016.

27. Klok FA, Dzikowska-Diduch O, Kostrubiec M, et al. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost. 2016; 14: 121-8. doi:101111/jth113175.

For citation

Tyurin V.P., Pronin A.G. Modern realities of therapy of pulmonary embolism. Bulletin of Pirogov National Medical & Surgical Center. 2021;16(3):73-76. (In Russ.)